

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CD44

RRID:AB_2744396

Type: Antibody

Proper Citation

BD Biosciences Cat# 566506, RRID:AB_2744396

Antibody Information

URL: http://antibodyregistry.org/AB_2744396

Proper Citation: BD Biosciences Cat# 566506, RRID:AB_2744396

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD44

Description: This monoclonal targets CD44

Target Organism: mouse

Clone ID: IM7

Antibody ID: AB_2744396

Vendor: BD Biosciences

Catalog Number: 566506

Alternative Catalog Numbers: 566507

Record Creation Time: 20231110T033442+0000

Record Last Update: 20260829T161307+0000

Ratings and Alerts

No rating or validation information has been found for CD44.

No alerts have been found for CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mitra T, et al. (2026) MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion. Immunity.

Zheng MZM, et al. (2026) Immunodominance is a poor predictor of vaccine-induced T follicular helper cell quality. EBioMedicine, 125, 106185.

Xie X, et al. (2026) Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell reports, 45(1), 116838.

Huang X, et al. (2026) Opposing functions of distinct regulatory T cell subsets in colorectal cancer. Immunity, 59(1), 145.

Mitra T, et al. (2025) MEK-dependent bioenergetic demand drives terminal CD8 + T cell exhaustion. bioRxiv : the preprint server for biology.

Tzeng SF, et al. (2025) PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. Cancer discovery, 15(8), 1676.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T??cells. Cell reports. Medicine, 4(8), 101154.